A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to test different doses of abemaciclib to find the best dose in participants while receiving hormone therapy and radiation therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 lat
- •Potwierdzony histologicznie przerzutowy rak piersi w stadium IV
- •Planowana radioterapia (SBRT) przerzutu do kości
- •Potwierdzony dodatni receptor hormonalny
- •Potwierdzony ujemny HER2
- •Dowolna wcześniejsza linia leczenia dozwolona
- •Planowane wznowienie leczenia abemacyklibem po radioterapii
- •Ustąpienie ostrych skutków wcześniejszej chemio-/radioterapii
- •Zdolność połykania leków doustnych
- •Prawidłowa funkcja narządów
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- May 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Memorial Sloan Kettering at Basking Ridge (All protocol activities)
Basking Ridge, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, United States
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities )
Commack, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, United States
Memorial Sloan Kettering Cancer Center (All protocol activites)
New York, United States
Memorial Sloan Kettering Nassau (All protocol activities)
Rockville Centre, United States
Trial contact
Lior Braunstein, MD
Rui Wang, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.